Status:
TERMINATED
Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
Lead Sponsor:
West Virginia University
Collaborating Sponsors:
West Virginia Clinical and Translational Science Institute
Conditions:
Glioblastoma Multiforme
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Subjects will receive standard chemotherapy and Tumor Treated Fields (TTFields) and will also receive Carvedilol for 4 cycles of treatment. Carvedilol will start at 6.25 mg orally twice a day and be i...
Detailed Description
This will be a feasibility study to assess the use of a new PCR assay with response to standard chemotherapy treatment in the second line setting in glioblastoma multiforme (GBM). The change in direct...
Eligibility Criteria
Inclusion
- Grade IV Glioblastoma, receiving chemotherapy with or without TTfields.
- Progressive or recurrent disease requiring second line treatment
- evidence of progression of disease by brain MRI and are planned to receive chemotherapy
Exclusion
- Current use of another beta blocker that cannot be switched to carvedilol at the onset of the trial.
- Systolic blood pressure \<90 mmHg and/or heart rate \<60 bpm without hypertensive medications
- Allergy to beta blockers
- Severe or uncontrolled asthma or COPD (chronic obstructive pulmonary disease)
Key Trial Info
Start Date :
July 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 17 2021
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03861598
Start Date
July 19 2019
End Date
June 17 2021
Last Update
September 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
WVU Cancer Institute - Mary Babb Randolph Cancer Center
Morgantown, West Virginia, United States, 26506